Other languages Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
2.645 ^USD	-2.40%		-7.84%	-21.28%

May. 02	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	MT
May. 01	Malin Corp investee signs agreement with Astellas Pharma	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	May. 01
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	Apr. 08
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	Mar. 25
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Poseida Therapeutics, Inc. Announces Executive Changes	Mar. 07
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	Dec. 11
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting	Dec. 10
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Poseida Therapeutics, Inc. Announces Board Changes	23-10-10
Poseida Therapeutics, Inc. Announces Chief Executive Officer Changes	23-10-10
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain	23-08-07
Poseida Therapeutics Says US FDA Clears Investigational New Drug Application for B-cell Malignancies Treatment Candidate	23-07-05
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Poseida Therapeutics, Inc. Appoints Kristin Yarema as President, Cell Therapy	23-04-12
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09
Poseida Therapeutics, Inc. Appoints Five New Members to Its Gene Therapy Scientific Advisory Board	23-03-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Other languages

Filters